Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 779

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 779
---
 The acquisition of Adgero Biopharmaceuticals Holdings, Inc. also triggers IRC section 382 on the pre-acquisition NOLs. An analysis for IRC section 382 has not been performed at this time on the pre-acquisition NOLs.

F-26

10. Commitments and contingencies The Company has the following obligations over the next five fiscal years ending June 30, 2028: Clinical development The remaining commitments relating to contracts for drug manufacturing, clinical study management and safety for contracts the Company has entered into for its clinical trials as of June 30, 2024, is $ 1,852. Pursuant to the commitments for clinical trials, the Company has paid a total of $ 205in deposits related to study initiation and certain study costs (note 3). These deposits are available to be applied against invoices received from the contract research organization but have not been netted against the Company’s commitments for the fiscal year ended June 30, 2024. Office lease The Company currently rents its shared head office on a one-yearrenewable lease at $ 2.4per year and until January 2024, rented its administrative offices on a month-to-monthbasis at a total rate of $ 1.90(CA $ 2.5per month) per month. During the year ended June 30, 2024, the Company recorded a total of $ 14as rent expense (2023 - $ 39).

11. Supplementary statement of cash flows information

|                                                                 |     | Year endedJune 30,2024 |     |     | Year endedJune 30,2023 |     |
| Series C Preferred Stock common stock dividend (note 8)         |     |                        | 173 |     |                        | 362 |
| Series A Preferred Stock cash dividend in accounts payable      |     |                        |   2 |     |                        |   — |
| Non-cashissue costs (note 8)                                    |     |                        |   — |     |                        | 289 |
| Equipment additions reclassified from prepaid expenses          |     |                        |   — |     |                        | 447 |
| Conversion of Series C Preferred Stock to common stock (note 8) |     |                        | 393 |     |                        |   — |
| Income taxes paid                                               |     |                        |   — |     |                        |   — |
| Interest paid                                                   |     |                        |   — |     |                        |